Letters
Challenge of multimorbidity
Amplifying the impact of clinical pharmacology and therapeutics
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m717 (Published 27 February 2020) Cite this as: BMJ 2020;368:m717
- Emma H Baker, professor of clinical pharmacology1,
- Jamie Coleman, professor of clinical pharmacology2,
- David Webb, professor of clinical pharmacology3
- 1St George’s, University of London, London SW17 0RE, UK
- 2University of Birmingham, Birmingham, UK
- 3University of Edinburgh, Edinburgh, UK
- ebaker{at}sgul.ac.uk
As clinical pharmacologists representing a truly generalist specialty, spanning all ages and organs, we welcome the call for rebalancing of specialist and generalist skills to improve care for patients with multimorbidity.1
Clinical pharmacology and therapeutics (CPT) arose in the last century in response to the explosive development of new drugs and parallel evolution of medicines regulation. In the 1970s, the …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.